PMHNP Scope of Practice for ADHD in New York

If you’re a psychiatrist or psychiatric nurse practitioner considering telehealth for ADHD treatment, you’ve probably asked yourself: Can I legally prescribe Adderall or other stimulants through video visits? The answer is yes—through at least the end of 2026—but the details matter, and they vary significantly by state.

Let’s cut through the confusion. Between temporary federal extensions, pending DEA rules, and state-by-state differences in scope of practice, ADHD prescribers face a regulatory maze. This guide breaks down exactly what you need to know to practice legally and confidently in 2026.

The Federal Landscape: Where We Stand Right Now

Here’s the bottom line: Until December 31, 2026, providers can prescribe Schedule II ADHD medications via telehealth without an initial in-person exam, thanks to the fourth extension of COVID-era flexibilities announced by the DEA and HHS in January 2026.

This matters because the Ryan Haight Act—the federal law governing controlled substance prescribing—normally requires at least one in-person medical evaluation before any controlled prescription. During the pandemic, the DEA waived that requirement. They’ve now extended it through 2026 to give themselves time to finalize permanent telehealth rules while ensuring patients don’t lose access to care.

What’s Coming Next: Permanent DEA Rules

The DEA is working on three new telemedicine regulations that will likely take effect in 2027. Based on their January 2025 announcements, here’s what to expect:

Telemedicine Special Registration: The DEA plans to create a voluntary pathway for providers to obtain special registration authorizing controlled substance prescribing without in-person exams. This registration will require:

• Mandatory nationwide PDMP (Prescription Drug Monitoring Program) checks
• Strict patient identity verification during audio-video consultations
• Compliance with new platform registration requirements (telehealth companies themselves will need DEA registration)

The Established Patient Exception: If you’ve seen a patient in person at least once (or another provider in your practice has), the new telemedicine rules won’t apply. You can continue prescribing via telehealth freely.

For Providers Starting New Patients Online: You’ll likely need the special registration to continue treating patients you’ve never seen in person. The DEA hasn’t published final rule text yet, but expect it to include safeguards like the PDMP checks mentioned above—designed to prevent ‘pill mill’ behavior while preserving legitimate access.

The bottom line: Don’t wait until late 2026 to understand these changes. Providers who want to maintain uninterrupted ADHD patient flow via telehealth should plan to obtain the special registration when it becomes available.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State-by-State Breakdown: Where ADHD Telehealth Gets Complicated

Federal law sets the baseline, but states can add their own requirements—or restrictions. Let’s look at the six most important states for telehealth practice:

California: Progressive and Clear

The Good News: California doesn’t require an in-person exam beyond federal requirements. State law explicitly allows prescribing based on a telehealth evaluation that meets the standard of care—even asynchronous methods if clinically appropriate. There’s no California-specific prohibition on prescribing stimulants via video.

What You Need to Know:

• PDMP Requirement: You must check the CURES database (California’s PDMP) before the initial prescription and at least every 4 months for ongoing Schedule II therapy. This is mandatory, not optional.
• NP Practice Authority: California is transitioning to Full Practice Authority for nurse practitioners. By 2026, experienced NPs (those with 3+ years or 4,600+ hours under physician oversight) can practice and prescribe independently—including ADHD meds. New NPs still need supervising agreements until they qualify.
• Licensure: You need a full California license. The state isn’t part of the Interstate Medical Licensure Compact, so there’s no shortcut for out-of-state physicians.

Best For: Established psychiatrists and experienced PMHNPs ready for independence. California’s clear telehealth framework and large patient population make it attractive—if you can navigate the licensing process.

Texas: Physician-Only Territory for Stimulants

The Restriction: Texas prohibits nurse practitioners and physician assistants from prescribing Schedule II controlled substances in outpatient settings. Period. The only exceptions are for hospitalized patients, hospice care, or hospital ER emergency orders.

This means only physicians (MD/DO) can prescribe Adderall, Ritalin, or other stimulants for outpatient ADHD in Texas—whether via telehealth or in person.

What You Need to Know:

• For Psychiatrists: You have full authority to prescribe ADHD meds via telehealth, following standard controlled substance protocols. Texas is part of the IMLC, so out-of-state physicians can expedite licensing.
• For NPs/PAs: You can evaluate ADHD patients and provide therapy, but a Texas-licensed physician must write the actual stimulant prescription. If you’re joining a telehealth platform, ensure physician collaboration is built into the workflow.
• PDMP: Texas mandates PDMP checks for opioids, benzos, barbiturates, and carisoprodol—but not stimulants by law. Best practice? Check anyway. Reviewing patient prescription history protects you and your patients.
• E-Prescribing: Mandatory for all controlled substances in Texas (as of 2021). Make sure your EPCS (Electronic Prescribing of Controlled Substances) setup covers Texas pharmacies.

Best For: Psychiatrists who want a large market (second-largest state by population) and don’t mind the extra administrative steps. Not ideal if you’re an NP looking for independent prescribing authority.

Florida: The Psychiatric Disorder Exception

The Good News: Florida law explicitly allows telehealth prescribing of Schedule II controlled substances for ‘treatment of a psychiatric disorder’—which includes ADHD. This carve-out has been in place since 2019.

So a Florida-licensed psychiatrist or PMHNP can legally prescribe stimulants after a telehealth exam without an in-person visit, because ADHD qualifies as psychiatric treatment.

What You Need to Know:

• Out-of-State Telehealth Registration: Florida created a unique pathway for out-of-state providers. If you’re licensed in another state with a clean record, you can register with Florida’s Department of Health to provide telehealth services to Florida patients—including prescribing ADHD meds under the psychiatric exception. You still need a DEA registration covering Florida, but this avoids getting a full Florida license.
• NP Scope: Florida PMHNPs (those with psych nursing credentials and 2+ years post-grad experience under a psychiatrist) can prescribe stimulants without the 7-day quantity limit that applies to other Florida NPs for Schedule II drugs. However, they must practice under a protocol agreement with a supervising psychiatrist—psychiatric NPs were excluded from Florida’s 2020 independent practice law.
• PDMP: Florida’s E-FORCSE system requires providers to check patient controlled substance history before prescribing to patients 16 and older. Document every check.

Best For: Providers (especially out-of-state) looking to expand into a large market with clear telehealth rules. The psychiatric exception removes ambiguity, and the out-of-state registration pathway lowers barriers to entry.

New York: Aligned with Federal Flexibility

The Update: In May 2025, New York updated its regulations to explicitly allow controlled substance prescribing via telehealth consistent with federal law. The state removed a barrier that previously mirrored the Ryan Haight Act’s in-person requirement.

What You Need to Know:

• PDMP is Non-Negotiable: New York mandates checking the I-STOP/PMP registry before prescribing any Schedule II, III, or IV controlled substance. This means every time you prescribe a stimulant, you check the registry. New York enforces this strictly.
• E-Prescribing: Required for all controlled substances since 2016. No exceptions for ADHD meds.
• NP Independence: New York allows experienced NPs (3,600+ hours of practice) to work without a written collaborative agreement. They still need a defined collaborative relationship with a physician, but there’s no direct supervision or co-signing requirement. PMHNPs can prescribe stimulants with the same authority as physicians—no quantity limits specific to NPs.
• The 90-Day Supply Option: Here’s a practical advantage—New York allows up to a 90-day stimulant prescription for ADHD if you indicate the diagnosis code ‘B’ (for minimal brain dysfunction/ADHD) on the prescription. This reduces refill hassles for stable patients and improves compliance.

Best For: Experienced NPs who want near-full autonomy and psychiatrists comfortable with strict documentation requirements. New York’s alignment with federal rules makes it predictable, but the mandatory PDMP checks and e-prescribing add administrative load.

Pennsylvania: Collaboration Required for NPs

The Framework: Pennsylvania doesn’t have state-specific barriers to telehealth prescribing of stimulants beyond federal law. Telemedicine is permitted under standard-of-care guidelines, and psychiatrists have full authority.

The NP Restriction: Pennsylvania requires nurse practitioners to maintain collaborative agreements with physicians. For Schedule II prescribing:

• 30-Day Limit: CRNPs can prescribe up to a 30-day supply of Schedule II medications (including stimulants)
• Physician Approval for Continuation: Any refill beyond 30 days requires the collaborating physician’s approval—essentially a review/sign-off before month two begins
• This means a PA PMHNP treating ADHD via telehealth needs an active relationship with a psychiatrist who reviews cases at least monthly

What You Need to Know:

• PDMP: Pennsylvania requires checking the PDMP before the initial prescription of any controlled substance in a new course of treatment. Best practice is to check for every stimulant prescription, even though the law specifically mandates it for opioids and benzos each time.
• E-Prescribing: Mandatory for controlled substances since 2019 (Act 96). Set up EPCS before treating PA patients.
• IMLC: Pennsylvania joined the Interstate Medical Licensure Compact in 2022, making it easier for out-of-state psychiatrists to obtain a PA license and practice via telehealth.

Best For: Psychiatrists looking for a sizable mid-Atlantic market. NPs should only consider PA if they’re comfortable with ongoing physician collaboration and the 30-day refill approval requirement—which can work well in group practices with psychiatrists on staff.

Illinois: Two-Tier NP System

The Complexity: Illinois has both Full Practice Authority (FPA) APRNs and collaborative-practice APRNs, creating different rules depending on the NP’s credentials.

Full Practice Authority NPs (those with 4,000+ clinical hours under physician collaboration plus 250+ hours of additional training):

• Can prescribe Schedule II stimulants independently via telehealth
• No physician consultation required for ADHD meds (the consultation requirement only applies to Schedule II narcotic drugs like opioids and benzodiazepines—stimulants are Schedule II non-narcotics)
• This is the gold standard for NP autonomy

Collaborative Practice NPs (those who haven’t achieved FPA status):

• Limited to 30-day supply of Schedule II medications
• Require collaborating physician’s approval for any continuation beyond 30 days
• Physician must review their Schedule II prescribing monthly

What You Need to Know:

• Licensure: Illinois requires both a professional license and an Illinois Controlled Substance License to prescribe controlled drugs. This is an extra administrative step—out-of-state providers need to obtain the IL CS license in addition to their medical/nursing license.
• Physicians: Illinois is in the IMLC, so out-of-state psychiatrists can expedite licensing. Full prescribing authority with no special state restrictions on telehealth.
• PDMP: Not explicitly mandated for stimulants by law, but required for opioids and first-time benzos. Check it anyway as best practice.
• Prescribing Psychologists: Illinois allows psychologists with advanced training to prescribe some psychotropic meds—but they’re excluded from prescribing Schedule II substances, so they cannot prescribe ADHD medications. ADHD prescribing remains with physicians, NPs, and PAs.

Best For: Experienced PMHNPs seeking FPA (which gives true independence) and psychiatrists wanting access to a major Midwest market. The two-tier system works well if you understand where you fall—but collaborative NPs need physician backup for stimulant management.

The Economics: Why Telehealth Platforms Beat DIY Marketing

Let’s talk about the real cost of acquiring psychiatric patients—because most providers drastically underestimate it.

The True Cost of DIY Patient Acquisition

If you’re thinking about building your own telehealth practice through SEO, Google Ads, or directory listings, here’s the reality:

SEO takes 6-12 months of consistent investment (content creation, technical optimization, backlinks) before generating meaningful patient flow. Most solo providers don’t have the expertise or patience for this timeline.

Google Ads for mental health keywords cost $15-40+ per click. With conversion rates typically 2-5% (most clicks don’t turn into booked appointments), you’re looking at $200-400+ per booked patient—and that’s if your ads are optimized. Factor in:

• Agency/consultant fees for campaign management
• Ad spend during testing and optimization (failed campaigns = wasted money)
• Staff time to handle and qualify leads
• No-show rates from cold leads (often 20-30% for first appointments)

Directory listings (Psychology Today, Zocdoc) charge monthly subscription fees AND you compete with hundreds of other providers on the same page. Zocdoc charges $35-100+ per booking, but when you add the monthly subscription cost, your total patient acquisition cost adds up quickly. And you’re still doing all the heavy lifting—managing the profile, responding to inquiries, handling scheduling.

Bottom line: When you add up ALL costs—marketing spend, staff time, no-shows, months of investment before results, and failed campaigns—acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+ per patient. And there’s no guarantee of ROI.

The Platform Advantage: Guaranteed ROI

This is where a platform model like Klarity makes economic sense. Instead of gambling on marketing channels with uncertain returns, you pay a standard listing fee per new patient appointment—only when a qualified patient actually books with you.

What you get:

• Pre-qualified patients already matched to your specialty and availability
• No upfront marketing spend or monthly subscription fees
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow (diversified revenue)
• You control your schedule—only pay when you see patients

The real comparison: Would you rather spend $3,000-5,000/month on marketing with uncertain results, or pay only when a qualified ADHD patient books with you?

For most providers—especially those starting out or scaling up—a platform that handles patient acquisition removes the risk entirely. You’re essentially trading a fixed cost per booked appointment for the variable costs and time investment of DIY marketing. The ROI is guaranteed because you only pay when you see patients.

FAQ: ADHD Telehealth Prescribing in 2026

Q: Can I start treating ADHD patients via telehealth today without an in-person visit?

Yes, through December 31, 2026, under the federal extension. You must use live two-way video, conduct a thorough evaluation meeting standard of care, document the encounter, check your state’s PDMP, and follow all other controlled substance prescribing protocols. After 2026, you’ll likely need the DEA’s telemedicine special registration to continue treating new patients you’ve never seen in person.

Q: What happens after December 2026?

The DEA is finalizing permanent telemedicine rules expected to take effect in 2027. Providers will likely need a ‘Telemedicine Special Registration’ to prescribe controlled substances to new patients without in-person exams. The registration will require compliance with enhanced safeguards (nationwide PDMP checks, identity verification, etc.). Start planning now—don’t wait until the extension expires.

Q: Do I need separate licenses for each state where my patients are located?

Yes. You must be licensed in the state where the patient is physically located during the telehealth visit, not where you’re located. Some states offer shortcuts (Florida’s out-of-state telehealth registration, IMLC for physicians in compact states), but generally you need full licensure in each state you practice.

Q: As a psychiatric NP, can I prescribe ADHD meds independently via telehealth?

It depends on your state:

• Yes, independently: California (if you have FPA after 2026), New York (after 3,600 hours experience), Illinois (if you have FPA status)
• Yes, with physician collaboration/supervision: Florida (protocol with psychiatrist), Pennsylvania (collaborative agreement, 30-day limit), Illinois (without FPA)
• No: Texas (physicians only for Schedule II outpatient prescribing)

Check your specific state’s NP scope of practice rules above.

Q: What’s the difference between a collaborative agreement and supervision?

Collaborative agreement (PA, IL without FPA): The physician doesn’t need to see your patients or co-sign every prescription, but they must be available for consultation, review your practice periodically, and approve certain clinical decisions (like continuing Schedule II beyond 30 days).

Supervision (FL): More structured oversight, often with specific protocols, and the physician may need to review cases more frequently or be more directly involved in treatment decisions.

Independence/Full Practice Authority (CA after qualification, NY with experience, IL with FPA): You practice within your scope without physician oversight, though you may still consult colleagues as needed clinically.

Q: How do I check the PDMP in multiple states?

Most states require you to register for their PDMP system separately (CURES in California, E-FORCSE in Florida, I-STOP in New York, etc.). Some platforms integrate multiple state PDMPs through services like RxCheck or PMP InterConnect, which can query multiple states at once. When you join a telehealth platform, ask if they provide PDMP integration tools—it saves significant time.

Q: Can I prescribe 90-day supplies of ADHD medications via telehealth?

It depends on the state:

• New York: Yes, if you indicate the ADHD diagnosis code on the prescription
• Most other states: Limited to 30-day supplies for Schedule II by regulation or practice norms
• For NPs: Pennsylvania and Illinois (without FPA) restrict NPs to 30-day Schedule II prescriptions regardless

Always check your state’s specific quantity limits.

Q: What if my state’s rules conflict with federal rules?

When state and federal law conflict, you must follow the more restrictive rule. For example, even though federal law currently allows telehealth prescribing without in-person exams, if a state required it (none currently do for ADHD under mental health treatment), you’d need to comply with the state requirement. In practice, most states have aligned with federal flexibilities or have exemptions for psychiatric care.

Q: Do I need malpractice insurance that covers telehealth?

Yes. Many traditional malpractice policies automatically cover telehealth, but verify with your insurer. Some insurers charge slightly higher rates for telehealth or require specific riders. Also confirm your coverage extends to all states where you’re licensed and practicing. Most telehealth platforms require proof of malpractice insurance before onboarding.

Q: Is audio-only (phone) sufficient for prescribing ADHD medications?

No. Federal guidelines require live, two-way interactive audio-video communication for prescribing controlled substances via telemedicine (except for specific substance use disorder treatments like buprenorphine, which has different rules). ADHD evaluation and stimulant prescribing should be done via video to meet both federal requirements and standard of care.

Next Steps: Start Seeing ADHD Patients Via Telehealth

The regulatory landscape for ADHD telehealth is stable through 2026 and becoming more structured beyond that. If you’re a psychiatrist or experienced PMHNP, now is the time to establish your telehealth practice—before the 2027 rule changes require additional steps.

What to do now:

1. Verify your state’s specific requirements using the state summaries above
2. Get licensed in states where you want to practice (use IMLC if you’re a physician and it’s available)
3. Register for state PDMPs in your practice states
4. Set up EPCS (electronic prescribing of controlled substances) if you haven’t already
5. Consider platform vs. solo practice economics: Spending months and thousands of dollars on uncertain marketing, or joining a platform that delivers pre-qualified patients?

Ready to see patients without the marketing headaches?

Klarity Health connects psychiatrists and psychiatric nurse practitioners with ADHD patients who need your expertise. Our platform handles patient acquisition, scheduling, telehealth technology, and insurance credentialing—so you can focus on clinical care.

You control your schedule. You only pay when you see patients. No upfront costs, no monthly subscriptions, no wasted ad spend.

Join Klarity’s provider network and start building your telehealth ADHD practice today—with the patient flow and infrastructure to make it profitable from day one.

Sources and References

The following sources were consulted to ensure accuracy and timeliness of all regulatory information in this guide:

All regulatory information verified against primary sources (state statutes, regulations, and federal agency announcements) as of February 2026. No outdated pre-2024 information was used for dynamic policies. Providers should verify current requirements with their state medical boards and monitor DEA announcements for rule updates.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care